MENU
NGNE
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Neurogene (NGNE) Ownership - Who owns Neurogene?
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions... Show more
Profile
Industry
N/A
Address
535 W 24th Street
Phone
+1 855 508-3568
Employees
91
Web
https://www.neurogene.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
156.16M
P/E Ratio
N/A
Total Cash
138.99M
Projected Growth
N/A
Total Debt
14.53M
Revenue
925K
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
9.31
Total Debt/Equity
N/A
Revenue/Share
0.05 USD as % of share price
Fundamentals
NGNE
Capitalization
156M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
139M
Total Cash/Share
9.31
Total Debt
14.5M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.05%
Revenue
925K
ROE
N/A
Book Value
137M
P/B Ratio
0.50
Cash Flow
N/A
Earnings
-4.09
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
9.09
Current Revenue Per Employee
10164.83
Dividends Per Share - Security
N/A
EBITDA
-49.96M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-32.44
Shares Held By Institutions
796M
Shares Outstanding - Current
14.9M
Total Liabilities
26.7M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-57.765
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
535 W 24th Street
Phone
+1 855 508-3568
Employees
91
Web
https://www.neurogene.com